What Is the Impact of Luspatercept on the Genomic Landscape in Lower-Risk MDS?

Rami Komrokji, MD, Vice-Chair of the Malignant Hematology Department at Moffitt Cancer Center in Tampa, Florida, discussed an analysis from the COMMANDS study that evaluated the impact of luspatercept on the genomic landscape in patients with lower-risk myelodysplastic syndromes (MDS).

“Luspatercept was more effective in patients that had one to two, or three mutation burden, and it seems that there was some imbalance at the baseline with less mutations and patients that got erythroid-stimulating agents (ESAs).” he said.

The researchers also looked at patient responses based on restaging them according to the ISPSS-M and that analysis was favorable, he explained.

“We saw the analysis favoring luspatercept over ESAs across all the subtypes of the IPSS-M as well,” he said.